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Blood flow and pO2 changes after vascular-targeted PDT (V-PDT) or cellular-targeted 
PDT (C-PDT) using 5,10,15,20-tetrakis(2,6-difluoro-3-N-methylsulfamoylphenyl) 
bacteriochlorin (F2BMet) as photosensitizer, were investigated in DBA/2 mice with S91 
Cloudman mouse melanoma, and correlated with long-term tumor responses. F2BMet 
generates both singlet oxygen and hydroxyl radicals under NIR irradiation, which 
consume oxygen. Partial oxygen pressure was lowered in PDT-treated tumors and this 
was ascribed both to oxygen consumption during PDT and to fluctuations in oxygen 
transport after PDT. Similarly, microcirculatory blood flow changes as a result of the 
disruption of blood vessels due to the treatment. A novel non-invasive approach 
combining Electron Paramagnetic Resonance oximetry and Laser Doppler blood 
perfusion measurements allowed longitudinal monitoring of hypoxia and vascular 
function changes in the same animals, after PDT. C-PDT induced parallel changes in 
tumor pO2 and blood flow, i.e., an initial decrease immediately after treatment, followed 
by a slow increase. In contrast, V-PDT led to a strong and persistent depletion of pO2, 
although the microcirculatory blood flow increased. Strong hypoxia after V-PDT led to a 
slight increase of VEGF level 24 h after treatment. C-PDT caused a ca. 5-day delay in 
tumor growth, while V-PDT was much more efficient and led to tumor growth inhibition 
in 90% of animals. The tumors of 44% of mice treated with V-PDT regressed completely 
and did not reappear for over one year. In conclusion, mild and transient hypoxia after C-
PDT led to intense pO2 compensatory effects and modest tumor inhibition but strong and 
persistent local hypoxia after V-PDT caused tumor growth inhibition. 
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1. Introduction 
Photodynamic therapy (PDT) is a clinically-approved therapy based on the 
destruction of neoplastic tissues [1], selective occlusion of choroidal neovascularization 
secondary to age related macular degeneration [2], and potentially useful to treat 
infection by multi-antibiotic resistant organisms [3]. It involves the use of 
photosensitizer, molecular oxygen and light of a specific wavelength in order to generate 
reactive oxygen species (ROS, namely singlet oxygen and hydroxyl radicals) which cause 
apoptosis, autophagy or necrosis of the treated cells, the closure of the blood vessels and 
eventually an activation of anti-tumor immune response [4]. Thousands of 
photosensitizers have been tested in vitro and in vivo but only a few of them managed to 
reach clinical trials [5, 6]. The simultaneous fulfillment of all of criteria for ideal 
photosensitizer is extremely difficult, and the heterogeneity of pathologically altered 
tissues and their different interaction with the photosensitizer are additional challenges 
that must be addressed by the therapy. Recent advances in PDT suggest that a class of 
compounds that meet most of the requirements for ideal PDT agents are bacteriochlorin 
derivatives [7-22]. They are characterized by a very high molar absorption coefficients 
(ε≥100 000 M-1 cm-1) in the therapeutic window and therefore may be effective at lower 
concentrations and allow for a deeper penetration of light in tissue when compared to 
porphyrin derivatives. Recently, new synthetic bacteriochlorins attained the 
photostability, long lifetimes in the excited triplet states and high quantum yields in the 
generation of ROS, that are desirable for PDT photosensitizers. Moreover, some of them 
display low dark cytotoxicity, high phototoxicity, amphiphilicity and high accumulation 
in sensitive organelles such as the endoplasmic reticulum (ER) and mitochondria. In 
particular, in the family of halogenated sufonamide bacteriochlorins it was possible to 
identify a photosensitizer, 5,10,15,20-tetrakis(2,6-difluoro-3-N-
methylsulfamoylphenyl)bacteriochlorin (F2BMet, illustrated in Scheme 1) that closely 
 matches the properties of an ideal PDT photosensitizer and proved very efficient in vitro 
and in vivo [23, 24]. 
A properly designed photosensitizer may not have the expected therapeutic success if 
it is not used with an appropriate protocol. For example, PDT exerts a profound effect in 
the tumor tissue oxygenation level and the generation of ROS during the therapy may 
lead to depletion of oxygen in the tumor, which may impair the efficacy of the therapy 
[25, 26]. In order to avoid that oxygen consumption becomes a limiting factor in PDT, 
various authors proposed the fractionation of light irradiation, with short dark periods 
(150-200 s), to allow for tissue re-oxygenation [27-30]. Furthermore, tumor tissue 
oxygenation exhibits very heterogeneous response to PDT, both spatially in different 
tumors [31], and between tumors [32]. For photosensitizers that have the vasculature as 
the main target [30, 33, 34], the supply of oxygen to tissue might be limited due to 
vascular damage resulting from PDT. Occlusion of blood vessels and, in consequence, 
hypoxia can occur within a few minutes after the beginning of PDT. This effect may be 
reversible or irreversible, depending on the amount of the photosensitizer present in 
tissue and applied light dose. Even if vessels stay intact and their function remains 
unchanged immediately after treatment, irreversible vascular damage and collapse 
develops within hours, leading to hemorrhage and tissue necrosis. The expected decrease 
in tumor oxygenation, or increase in hypoxia, was observed in vascular-targeted PDT 
[27, 30, 35]. On the other hand, when tumor cells are targeted in PDT, limited oxygen 
consumption can lead to increase in oxygenation due to decrease in metabolic 
consumption of oxygen by cells [36]. Thus, understanding tumor tissue oxygenation 
before, during and after PDT is useful to obtain the optimal parameters for therapy, and it 
has even be suggested that monitoring of PDT-induced changes in tumor oxygenation 
may be a valuable prognostic indicator [37]. One of the indirect methods of hypoxia 
detection is assessing the presence of protein associated with, or induced by, hypoxia 
such as VEGF [38, 39].  
Accurate estimation of hypoxia in vivo remains a challenge, although various 
methods have been tested in vivo, such as pimonidazole retention or hypoxia-induced 
protein staining [40]. Remarkably, electron paramagnetic resonance (EPR) oxymetry 
allows for repetitive and non-invasive oxygen measurements in tumors of living animals 
 [41-44]. In particular, solid oxymetric microcrystals such as lithium phthalocyanine 
(LiPc) bring accurate and precise information on oxygen partial pressure in probe 
surroundings [45-46]. Likewise, optical methods, e.g. Laser Doppler Perfusion Imaging 
(LDPI), give access to non-invasive blood flow measurements. LDPI provides 
information on microcirculation of the surface tissues (up to mm) from the tumor surface 
and tumor surrounding area. Combining the two methods gives insight into tissue 
physiology in the local (EPR) and global (LDPI) scale, and provides the grounds to 
understand the roles of vasculature, microcirculatory blood flow and pO2 in the outcome 
of PDT. Scheme 2 illustrates how both techniques were implemented in this study. As 
both methods are non-invasive, longitudinal studies on hypoxia and vascular function 
may be performed in the same animals. The goal of this study is to determine pO2 and 
blood flow changes after vascular PDT (V-PDT, with a drug-to-light interval of 15 min) 
and tumor-cell targeted PDT (C-PDT, with a drug-to-light interval of 72 h) using a 
bacteriochlorin derivative and estimate how they correlate with therapy efficacy. In vivo 
measurements of pO2 in the tumor give estimates of the oxygen consumption changes 
during PDT, as well as of changes in its transport and metabolic consumption after PDT. 
Simultaneous measurements of microcirculatory blood flow reveal the disrupted function 
of blood vessels after PDT. Altogether, these experiments may verify the hypothesis that 
V-PDT massively destroys tumor vessels and leads to extreme hypoxia within the tumor, 
whereas tumor-targeted C-PDT preserves the oxygenation level in the tumor.  
2. Materials and methods 
2.1. Chemicals 
5,10,15,20-Tetrakis(2,6-difluoro-3-N-methylsulfamoylphenyl)bacteriochlorin 
(F2BMet or LUZ11) [23] was provided as a powder in sealed vials under protective 
atmosphere by Luzitin SA (Coimbra, Portugal). Solutions for intravenous (i.v.) 
administration were prepared by dissolving the desired amount of F2BMet in a certain 
volume of Cremophor EL – CrEL – (Sigma, Germany) mixed in 1:1 (v/v) proportion 
with ethanol 99.8% (POCH, Poland), followed by dilution by a factor of 50 with 0.9% 
NaCl aqueous solution, and then injection in the animals [24]. F2BMet is readily soluble 
in CrEL:ethanol, which forms micelles when added to the saline solution. This 
 administration vehicle is well tolerated and prevents the precipitation of the 
photosensitizer in the organism. The concentration of F2BMet in the administration 
vehicle was 200 mg/L. The F2BMet dose used in all animals was 2 mg/kg body weight, 
assuming a pure starting material. Medium for cell culture (RPMI, F10) and PBS 
(phosphate-buffered saline) were purchased from Biomed, Poland. Trypsin/EDTA, cell 
culture media and supplements, and animal serum were purchased from Biochrom 
(Berlin, Germany). Butorphanol (Butomidor) was obtained from Richter (Pharma AG, 
Wells, Austria). Medetomidine hydrochloride (Cepetor, ScanVet, Warszawa, Poland) and 
ketamine (Bioketan, Biowet Pulawy, Poland) were used as anesthetics during in vivo 
experiments.  
2.2.  Absorption and fluorescence spectra 
UV/VIS absorption spectra were recorded in quartz cuvettes with Shimadzu 2100 
spectrophotometer. Fluorescence studies were carried out using a Luminescence 
Spectrometer LS 50B (Perkin–Elmer). 
2.3 Tumor model 
S91 Cloudman mouse melanoma cell line (subline I3) was described previously [19-
21]. The cells were grown as monolayers in the RPMI medium, supplemented with 5% 
fetal calf serum and antibiotics (penicillin, streptomycin) at 37 °C in a humidified 
atmosphere containing 5% CO2, as described elsewhere [47-48]. Shortly before tumor 
inoculation, cells were washed with PBS and harvested by trypsynization. After 
centrifugation cells were washed again with warm PBS, and 0.5 ×106 of cells were 
administered intradermally in 0.05 ml into the hind right leg of DBA/2 mice. The tumors 
grew visible 7-10 days after implantation and their volumes (V) were estimated on the 
basis of their three perpendicular diameters according to formula: V= π/6(a×b×c), where 
a, b, and c stand for the respective perpendicular diameters of the tumor.  
2.4 Animal model and experimental groups  
Male DBA/2 mice, implanted with the Cloudman S91 melanoma, were 3-4 months 
old and about 25 g each. The mice were kept on a standard laboratory diet with free 
access to drinking water in community cages and a 12 h day/night regime. The animals 
 used in the present study were obtained from the animal breeding facility at Mossakowski 
Medical Research Centre Polish Academy of Sciences, Warszawa, Poland. Before the 
experiments animals were quarantined for 2 weeks. The use of these animals for 
experimental purposes was approved by the Jagiellonian University Committee for Ethics 
of Experiments on Animals (permission no. 114/2009, 76/2011 and 42/2014). 
In order to make possible measurements of pO2 and blood flow at the same time 
point, two separate sets of animals were used. Within each set the animals were divided 
into the following experimental groups: (a) V-PDT: light irradiation given 15 min after 
PS injection, (b) C-PDT: light irradiation given 72 h after PS injection, (c) light control - 
animals treated with carrier for PS and light only, (d) dark control - animals treated with 
PS only, without light. Randomly chosen animals were euthanized at certain time points 
for other tests, and all the remaining mice were observed for survival and acute effects, 
such as erythema and edema.  
2.5 Biodistribution experiments 
The i.v. administration of the drug formulation was done when the tumor attained a 
volume of 30-60 mm3 in each animal, which usually took 10 days after the inoculation.  
The formulation, corresponding to a 2 mg/kg of F2BMet, was slowly injected in the tail 
vein of each animal, and the biodistribution was evaluated at 2 time points after 
administration: 15 min and 72 h. At the selected time points post injection, the mice were 
anesthetized with ketamine and xylazine. For each animal, the following organs and 
tissue samples were collected separately and weighed: tumor, muscle, skin, liver, spleen, 
kidneys, intestines, heart, lungs and blood. The content of F2BMet in the tissue samples 
was determined by fluorescence measurements. In order to extract the pigments, tissue 
samples were separately homogenized in 1 ml of ice-cold solution ethanol:DMSO 
(75:25) during 1 min, using a tissue homogenizer Di25 basic, IKA-Werke, GMBH&Co 
(Stauten, Germany). The homogenate was centrifuged at 1800g for 1 min at 5 ºC, the 
supernatant was collected and the pellet was re-extracted 3 more times using the 
procedure described above, to ensure a complete recovery of the drug. The extracts were 
pooled and the final volume adjusted to 5 ml. The fluorescence analysis of the extracts 
was done less than 3 h from the harvest. The samples were excited at 505 nm and the 
 fluorescence spectra were recorded in the range between 600 and 800 nm. The amount of 
F2BMet in the tissues is reported as the average from 5 animals, with the standard error of 




2.6 PDT treatments 
When the tumors reached a volume of 30-50 mm3, an appropriate volume of a freshly 
prepared F2BMet drug formulation was administered i.v. in each mice to give at a dose of 
2 mg/kg body weight. Before the PDT treatment, animals were given subcutaneously 
(s.c.) butorphanol at a dose 3 mg/kg (Butomidor, Richter Pharma AG, Wells, Austria) to 
alleviate the pain and then anaesthetized by i.p. injection of the mixture of 0.1 mg/kg 
medetomidine hydrochloride (Cepetor, ScanVet, Warszawa, Poland) and 50 mg/kg of 
ketamine (Bioketan, Biowet Pulawy, Poland). During the anesthesia the animals were 
kept at stable temperature around 35 °C using heating pad. 
Two types of PDT protocols were tested: vascular-targeting V-PDT (15 min time 
interval between PS and light administration), and tumor cellular-targeting C-PDT (72 h 
interval between PS and light administration). In all cases the tumors were irradiated 
from distance of 1 cm for 30 minutes using a 750 nm laser light at a final dose of 86 
J/cm2. As a light source a 750 nm Hamamatsu diode laser LA0873 with power supply 
ThorLab 500 mA ACC/APC was used. We selected a low laser fluence rate for this study, 
48 mW/cm2, which is less than half of that typically used in PDT, to minimize 
heterogeneous oxygen depletion during the irradiation. A laser power meter (Field MaxII-
TO, Coherent, Portland, USA) was used to monitor the light power. 
2.7 ROS detection 
The 3’-p-(aminophenyl)fluorescein (APF), a probe with higher selectivity towards 
hydroxyl radicals, and Singlet Oxygen Sensor Green® (SOSG), a probe specific for 
singlet oxygen, were employed for detection of ROS in aqueous solutions during 
illumination. APF reacts preferably with hydroxyl radical to produce fluorescein, which 
emits at 530 nm when excited at 488 nm. SOSG reacts very specifically with singlet 
 oxygen to generate a fluorescent endoperoxide that emits at 525 nm when excited at 505 
nm. Bacteriochlorin solutions in DMSO were diluted to a final concentration of 5 μM per 
well in PBS (final [DMSO] ≈ 0.4%). Next, the probes SOSG or APF were added to each 
well to a final concentration of 10 μM. The solutions were irradiated using the same light 
source as for PDT treatment for various time intervals up to 30 minutes, which 
correspond to a maximum dose of 86 J/cm2 at 48 mW/cm2. The microplate reader (Tecan 
Infinite M200 Reader) was used for acquisition of fluorescence signal from the probes 
immediately before and after each illumination period. When APF was employed, 
fluorescence emission at 515 nm was measured upon excitation at 490 nm. With SOSG, 
the corresponding emission and excitation wavelengths were 525 and 505 nm, 
respectively. The wells were always exposed to air and oxygen depletion in the solution 
is unlikely to occur at the low fluence rate used in this experiment. 
2.8 Tumor pO2 measurement 
Crystalline oxymetric probe lithium phthalocyanine (LiPc, a gift from Prof. Harold 
Swartz, EPR Center, Dartmouth Medical School, Dartmouth, USA) was inserted into the 
S91 Cloudman melanoma tumor growing in the right hind leg of DBA/2 mice. 
Approximately 0.1 mg of LiPc in crystal form was implanted per mouse. No side effects, 
such as inflammation, redness, edema, or morphological changes (as detected by 
ultrasonography) were observed after LiPc implantation. The EPR measurements started 
3 days after LiPc implantation (see Fig. S1 in the Suplementary Materials) to allow for its 
stabilization in the tissue [49-50]. Mice under anesthesia were placed in an animal holder, 
with the right hind leg perpendicular to the mouse support. The mouse leg was placed 
closely to the surface of the coil. The leg was immobilized carefully making sure that 
blood flow was not perturbed. EPR spectra were taken using the following parameters: 
microwave frequency 2.13 GHz (S-band), microwave power 4 mW, sweep field 5 G, 
gain 2×105, modulation amplitude 0.08 G, time constant 300 ms, sensitivity 10 mV. For a 
single measurement 3 scans, 512 s each, were taken and averaged. The pO2 was 
determined from the linewidth of the EPR spectrum of the LiPc signal. EPR Fitting 
Software v3.0.2K (obtained from dr. Ben Williams and Tom Matthews, EPR Center, 
Dartmouth Medical School) was used to fit the linewidth of the LiPc signal. The 
linewidth was then recalculated for pO2 using the calibration curve, obtained from spectra 
 of LiPc crystal in different gaseous mixtures, using a coefficient of 5.79 ± 0.42 mG/mm 
Hg (in the range between 0 and 56 mmHg).  
2.9 Blood perfusion measurements  
Laser Doppler Perfusion Imaging (LDPI) is a noncontact laser imaging technique for 
the measurement of superficial blood perfusion. Blood perfusion was measured with a 
LDPI Periscan system II (Perimed AB, Järfälla, Sweden) before, 15 min and 3 h after the 
treatment and then every 24 h for several consecutive days. The skin on the leg with the 
tumor was scanned with pulsed laser light (670 nm, 1 J maximal output power). Photons 
that are dispersed by moving blood cells undergo a change in wavelength/frequency (a 
Doppler shift), while photons that encounter static structures return with the same 
frequency to the detector. The perfusion can be calculated since the magnitude and 
frequency distribution of the Doppler-shifted light are directly related to the number and 
velocity of blood cells but unrelated to their direction of movement. Penetration depth is 
around 0.5-1 mm according to the manufacturer. The color images of the 
microcirculatory perfusion results are expressed as arbitrary units, and the scanning 
system is calibrated before each set of measurements using the motility standard 
provided. For quantitative analysis, raw read-out data (in V) from the tumor area were 
presented as a histogram (using Image J software). Microcirculatory blood perfusion was 
expressed as the ratio between median blood flow measured in the tumor area to that 
measured in the same region in normal contralateral leg. Likewise, measurement of 
perfusion in the area of vena saphena lateralis in the tumor leg was referenced to the 
same area in the normal leg. This eliminates differences in blood perfusion, such as 
temperature, anesthesia level and the general mouse condition. For a single animal 
median values of blood flow were calculated with SD and for a group of animals values 
were calculated as weighted means of medians with SEM. 
2.10 PDT induced edema and erythema in the treated legs 
Edema was expressed as tumor volume relative to stage before treatment. Erythema 
was evaluated on the scale between 0 and 2, with 0 – no erythema, 0.5 - minor, 1 – 
moderate, 2 – intense erythema. 
2.11 Processing the samples and VEGF ELISA assay  
 Whole tumors were isolated 24 h after illumination and stored in liquid nitrogen no 
longer than 2 days. The samples (17 ± 3 mg) were homogenized (30-times) in 100 µl ice-
cold PBS. An additional 100 µl of ice-cold PBS was added and samples were sonicated 
for 5 min in room temperature.  Homogenized samples were centrifuged at 10,000 rpm 
for 10 min in 4 °C. The supernatants were collected and concentration of protein was 
measured by the Bradford method. All samples were stored at -24°C for less than 1 day. 
Quantitative sandwich enzyme immunoassay for VEGF (ELISA assay) was performed 
according to manufactured protocols (R&D, MMV00). In each well 20 µg of total protein 
was added. Each tumor sample was prepared as duplicate. 
2.12 Ultrasonography 
An ultrasonographic imager Vevo 2100 (VisualSonics, Toronto, Canada) was used 
for obtaining the images of tumors and localization of LiPc crystals (B-mode). Doppler-
mode was used to images density of vasculature near oxygen spin probe (0.25 mm radius 
around LiPc). Vevo 2100 1.2.0 software was employed for tumor and LiPc delineation.  
2.13 Statistical analysis 
Group mean values of pO2 and blood flow were calculated as weighted means, with 
variance as weights. Statistical significance was determined by Student t-test, Welch t-
test, U-test or Fisher test. Kaplan-Meier statistical significance was determined using 
Wilcoxon analysis. Regression coefficients were determined using “fit linear” Origin 
routine and Statistica, with errors as weights, when possible. Histograms of blood 
perfusion values were analyzed using matrices of perfusion values expressed in absolute 
values measured [V]. Only tumor area pixels were included in histograms. Difference 
between tested groups was accepted as significant for p<0.05 or as described in figures 
captions. 
3. Results 
3.1. Spectroscopic properties of F2BMet in the administration vehicle 
F2BMet exhibits the characteristic bacteriochlorin absorption spectrum with a broad 
near-UV Soret feature with two peaks, a near-infrared Qy band of comparable intensity 
and only a narrow band in the green (≈510 nm). Representative spectra recorded in the 
 vehicle used for i.v. injections in animals in vivo studies are shown in Figure 1. The 
Qy(0,0) absorption maximum of F2BMet is at 748 nm in the vehicle, and the Qy(0,0) 
fluorescence peak is bathochromically shifted by 2 nm. The vehicle used in the in vivo 
experiments contains CrEL:ethanol:NaCl 0.9% in a 1:1:98 (v/v/v) proportion. The 
infrared absorption coefficient of F2BMet dissolved in this formulation (εmax=125 000 M-
1 cm-1) is smaller than in ethanol (εmax=140 000 M-1 cm-1) [23]. A bacteriochlorin with 
molar absorption coefficient in excess of 100 000 M-1cm-1 in this formulation is evidence 
for the absence of aggregation and enables the efficient use of F2BMet at much lower 
concentrations than its porphyrin and chlorin analogues. Moreover, light at 748 nm 
penetrates deeply into human tissues without any side effects. 
3.2. Overview of blood flow and oxygenation in tumors  
Figure 2 shows that blood perfusion on the surface of untreated tumors is 
heterogeneous. The histograms of blood perfusion display a wide variety of distributions, 
with examples of wide, narrow, single-or double-peaks. Apparently, heterogeneous 
microcirculation networks already exist in untreated tumors. Figure 3 shows images of 
the superficial microcirculatory blood flow in the leg of mice with and implanted S91 
tumor, before PDT and 15 min, 3 h or latter times after V-PDT or of C-PDT. Shortly after 
V-PDT the blood perfusion is decreased, and then a gradual increase up to the maximum 
on day 7 is observed (Figure 3A, B, 3.1). The increase in blood perfusion after C-PDT 
(Figure 3 C, D, 3.2) attains a higher value than after V-PDT in the same time scale. 
Figure 4 presents representative changes in pO2 observed for animals subject to V-
PDT and C-PDT. It is very striking that the tissue pO2 level recorded immediately after 
V-PDT, and for at least the subsequent 24 h, decreased to nearly zero (Figure 4.1). A 
slight increase in pO2 was later observed in one animal, reaching 10 mmHg in day 4 (Fig. 
4.1A), but the pO2 value in the other animal did not recover in the observation time (Fig. 
4.1B). In contrast, C-PDT led to a transient decrease in pO2, lasting usually no more than 
3 h, followed by a recovery of pO2. In one animal, the tumor tissue pO2 increased even up 
to 35 mm Hg (Fig. 4.2D), which is much higher than the value before PDT. The 
ultrasonographic images of individual animals show sagittal slices of murine legs with 
tumor cross section delineated in green and position of oxymetric spin probe LiPc 
 marked in red (Fig. 4A-D). Analysis of all tumors indicated that there was no relationship 
between LiPc position within the tumor and pO2 reading, i.e. the depth of the probe 
location in the tumor does not determine the pO2 reading (compare Figures S2 and S3 in 
the Supplementary Materials). 
Figure 5 presents the mean pO2 and blood flows of V-PDT and C-PDT treated 
animals, as well as of control groups. V-PDT and C-PDT protocols lead to statistically 
significant differences in tumor pO2 values. Surprisingly, both protocols led to a strong 
stimulation of blood flow 2 days after the treatment, which was sustained for two weeks 
in the case C-PDT. 
3.3.  C-PDT, but not V-PDT induced parallel changes in tumor pO2 and 
blood flow 
A slight reduction in pO2 was noted immediately after V-PDT, which was partially 
recovered in the following 24 hours, and then deceased to baseline values (Fig. 5A). In 
contrast, blood perfusion decreased in the first 24 h after V-PDT, and then increased from 
day 2 to day 7, to a value 8 times higher than at day 1. 
The mean pO2 in tumors treated with C-PDT strongly decreased immediately after 
illumination (from 3 mmHg to 0 mmHg), but then increased up to 12 mmHg at 72 h and 
remained high. The mean blood flow did not change in the first 24 h after C-PDT, and 
then gradually increased up to a maximum perfusion 5 times higher on day 9. Both pO2 
and blood flow exhibited similar pattern of changes in C-PDT, namely a pronounced 
increase after PDT and high values one week after PDT. However, the fast reduction in 
pO2 immediately after illumination is not associated with a corresponding blood flow 
change (Fig. 5B). 
Maximal blood perfusion in tumors was reached 7 to 9 after PDT for both protocols, 
and was 8 and 5 times higher for V-PDT and C-PDT than for a normal leg, respectively. 
Both protocols led to an initial decrease in pO2. However, on average, V-PDT decreased 
pO2 from 2 to 1 mmHg and maintained pO2 below 2 mmHg in the first 3 days after PDT, 
whereas C-PDT depleted pO2 from 3 to 0.5 mmHg but then it increased up to 12 mmHg 
in the third day after PDT. Both pO2 and blood flow control values were changed slightly 
 in the dark (Fig. 5D), whereas an increase up to 6 mmHg in pO2 value was observed after 
illumination  (Fig. 5C). 
 
 
3.4 Vascular targeted PDT enhances VEGF level 
Figure 6 shows that the VEGF levels were slightly increased in tumors 24 hours after 
V-PDT, but not after C-PDT. This parallels pO2 depletion and strong hypoxia in tumor 
tissue after V-PDT (Fig. 5). It is worth noticing that distribution of this protein content 
was skewed in all groups suggesting high heterogeneity in VEGF level. However, in V-
PDT group VEGF distribution became normal, indicating more homogenous response.  
3.5 Biodistribution of F2BMet after 15 min and 72h post injection 
The biodistribution of F2BMet were studied after the administration in the tail vein of 
DBA/2 mice of a drug dose of 2 mg/kg in 0.1 ml of vehicle. The solvent mixture 
employed was CrEL:ethanol:NaCl 0.9% in a 1:1:98 (v/v/v) proportion. F2BMet is very 
soluble in this vehicle, and the solvent mixture was not toxic to the mice. Five animals 
per group were sacrificed at different time points (15 min and 72 h post injection) and 
F2BMet was extracted from the target tissues, including tumor, muscle, skin, liver, 
kidneys, heart, lungs, spleen and blood. Figure S4 in Supplementary Materials shows 
representative fluorescence spectra of F2BMet extracted from tumor, muscle and skin 72 
h after i.v. injection. The largest concentrations of F2BMet, in terms of µg of F2BMet per 
g of wet tissue, after 15 minutes from injection were observed in the blood, spleen, lungs, 
tumor and liver and are presented in Table 1. Interestingly, 72 hours after F2BMet 
injection its concentration in tumor increased to more than 5 µg per 1 g of wet tissue and 
was the highest amount among all studied organs/tissues. The tumor-to-skin (T/S) and 
tumor-to-muscle (T/M) ratios at this time point are 3.8 and 4.3, respectively. Tumor to 
surrounding tissues ratios after 15 min and 72 h are collected in Table 2. 
3.6 Photodynamic efficacies after V-PDT and C-PDT  
Figure 7 shows Kaplan-Meier plot with percentage of animals with local tumor 
control, i.e. tumor volume less than 400 mm3. Half of animals survived until day 10 in 
 controls, day 16 after C-PDT, whereas after V-PDT 50% were still alive on day 47. In 
this group of animals in 44% of mice tumor regressed and did not reappear for 1 year (the 
end of observation time). This high photodynamic activity towards very resistant 
melanoma tumors may be explained by efficient generation of both singlet oxygen and 
hydroxyl radicals. Fig. 8 shows that F2BMet activates both APF and SOSG, but the 
saturation of the fluorescein signal occurs at a lower light dose than that of the 
endoperoxide. This is assigned to a faster consumption of APF, which would be 
consistent with the ability of F2BMet to generate both hydroxyl radicals and singlet 
oxygen under illumination in biological media [23], that would react with APF to release 
fluorescein, as opposed to SOSG that reacts selectively with singlet oxygen. The 
hydroxyl radical is a most cytotoxic species and is expected to be a major contributor to 
tumor damage in PDT with F2BMet. 
The kinetics of the tumor growth of individual animals is presented in 
Supplementary Figure S5. Some acute reactions to PDT treatment were observed, such as 
edema and erythema at the illuminated site. Erythema usually appeared on day 2, attained 
its maximum at day 3, and lasted until day 5-6. Interestingly, erythema was present in 
fewer animals after V-PDT than after C-PDT (Fig. 9A). Edema of the leg with the tumor 
was maximal at 3 h after V-PDT, reaching a volume 30 times higher than before the 
treatment, and then decreased up the day 4 (Fig. 9B). The maximal edema in animals 
treated with C-PDT was 15 times higher than the tumor volume before the treatment at 
day 1, but significantly smaller than the maximal edema observed with V-PDT (Figure 
9B). The gradual increase of volume seen in the light control reflects the tumor growth 
(Fig 8B).  
Figure 9C shows changes in relative blood flow after PDT in the region of the vena 
saphena lateralis. A gradual decrease in blood flow in the first 24 h was seen both after 
V-PDT and C-PDT. After C-PDT the blood flow returned to the normal level within 3-4 
days, whereas after V-PDT the strong inhibition of blood flow was maintained for 4 days 
and suddenly returned to the normal level on day 5. 
4. Discussion 
We have recently shown that when halogenated and sulfonated bacteriochlorins 
absorb NIR radiation, they generate high amounts of singlet oxygen and superoxide ion 
 radicals and, subsequently, hydrogen peroxide and hydroxyl radicals [12]. The combined 
effects of singlet oxygen and hydroxyl radical make bacteriochlorins more promising and 
effective in PDT than the corresponding chlorins [51-52]. Exchanging sulfonic to 
sulfonamide groups resulted in an even more significant enhancement of 
photocytotoxicity in vitro [20] and in vivo [21]. The earlier saturation of the signal 
generated by APF with respect to that generated by SOSG, shown in Fig. 8 for the same 
concentrations and fluence rates, is consistent with the generation of large quantities of 
both singlet oxygen and hydroxyl radicals when F2BMet is illuminated, because SOSG 
reacts only with singlet oxygen but APF can be consumed in reactions with hydroxyl 
radicals and singlet oxygen. The conditions employed in Fig. 8 are similar to those of in 
vivo experiments (the same light source, fluence rates and light doses). A recent study 
comparing V-PDT and C-PDT protocols with F2BMet in BALB/C mice with 
subcutaneously implanted CT26 cancer cells showed that V-PDT could lead to a higher 
rate of tumor remissions than C-PDT [24]. Fig. 7 shows that V-PDT also leads to better 
treatment outcome than C-PDT in a different tumor model. In addition to these 
extensions of previous work, we now report for the first time non-invasive EPR oximetry 
and LDPI measurements that unravel the underlying reasons for the difference between 
V-PDT and C-PDT.  
Non-invasive measurements of tumor pO2 (EPR) and microcirculatory blood flow 
(LDPI) provide complementary views on physiology of the vasculature after treatment. 
Moreover, they give information both on the local (tumor area around the LiPc probe) 
and on the global (superficial microperfusion of the tumor and surrounding areas) scales.  
Earlier studies on tumor pO2 after PDT suggested that different patterns in pO2 and blood 
flow could emerge after V-PDT or C-PDT [53-55]. A strong depletion in pO2 and blood 
flow should be expected after V-PDT, whereas C-PDT was anticipated to produce a 
temporary increase in pO2. However, the patterns emerging from our studies are more 
intricate. 
V-PDT is an effective therapeutic approach using an array of photosensitizers [24, 30, 
34, 55]. It aims at the destruction of tumor vessels, limiting the tumor nutrition and 
controlling tumor growth. In V-PDT light is applied very soon after the photosensitizer 
administration, while it is still within the vascular compartment. Alternatively, in tumor 
 cellular-targeted PDT (C-PDT), the drug-to-light interval is increased to take advantage 
of the accumulation of the photosensitizer in tumor cells and of its faster clearance from 
normal tissues. C-PDT aims at the selective destruction of the tumor tissue while sparing 
the normal tissues. Biodistribution studies have demonstrated that tumor-to-muscle or to 
skin tissue ratios peak at 24-72 h post-i.v. administration of the photosensitizer [21, 24, 
45], and in this work we performed C-PDT at 72 h post-i.v. administration of F2BMet 
when the tumor-to-muscle ratio attains 4.3. 
 PDT caused changes in tumor pO2 and microcirculation blood flow that are specific 
to each protocol. V-PDT led to a decrease in pO2 for up to several days, indicating deep 
and long-lasting (chronic) hypoxia. A slight increase in VEGF level 24 h after V-PDT 
indirectly confirms hypoxia induced by the therapy. However, the decrease in pO2 after 
C-PDT lasted for only a short period of time and was followed by a large increase in pO2 
that lasted for 4-5 days after therapy. The decrease right after therapy might be explained 
by consumption of oxygen during PDT. The increase in pO2 to 6 mmHg at 3 h post-PDT, 
and then to 10 mmHg at 24 h post-PDT, probably results from compensatory delivery of 
oxygen due to previous consumption during long time of irradiation (30 min) as it is 
illustrated in Fig. 9A. C-PDT effectively destroys tumor cells (histology, data not 
shown), leading to decreased oxygen metabolism, and this may allow the high pO2 levels 
to last for several days. Tumor regrowth started around day 5, which correlates with 
decrease in pO2 level observed henceforward. 
The question arises as to the influence of these effects on the therapeutic outcome. 
Figure 10A expresses the decrease in pO2 due to therapy, Δ(before–immediately after), 
as a function of the increase in pO2 within 24 h after the treatment, Δ(24h–15min). This 
reveals that in C-PDT these pO2 levels are correlated (R2=0.84), i.e., the oxygen 
consumption during PDT evokes a compensatory response leading to an increase in pO2 
post-PDT. Such a correlation was not found for V-PDT, where the decrease in pO2 post-
PDT did not recover, and suggests an almost complete destruction of the vasculature. 
Figures 5A and 5B show that V-PDT produces chronic hypoxia in the tumor, and the 
Kaplan-Meier plot in Figure 7 show that this is critical for the therapeutic outcome of 
PDT.  
 The value of pO2 in the tumors immediately after V-PDT correlated with efficacy 
of the therapy regarded both as tumor volume on day 5-7 (R2=0.71, p=0.02) and time-to-
tumor volume of 400 mm3 (R2=0.77, p=0.01). For C-PDT no such correlations were 
found. It is worth noticing that neither changes in blood flow, Δ(24h–15 min), nor in 
ΔpO2 , Δ(before- immediately after), correlated with therapeutic efficacy. Rather than the 
variation in pO2, it is the absolute values of pO2 (0-1 mm Hg) that determines the efficacy 
of V-PDT (Fig. 10B). Minimal pO2 after PDT correlates with lifetime of animals (N=7, 
R2=0.76, p=0.047). This corroborates the conclusions that strong local hypoxia due to 
therapy is required to inhibit the tumor growth and increase life expectancy.  
We suggest that the existence of a very strong hypoxia (0 mmHg, Fig. 9B) is a 
good predictor of the therapy outcome. Partial dysfunction of the blood flow does not 
guarantee a good long-term tumor response to PDT and, conversely, might even have a 
stimulatory effect on tumor growth (especially with simultaneous increase in VEGF in 
the surrounding tissue). An increase in blood flow due to C-PDT on day 5-7 correlated 
with tumor volume the same day (the higher the increase in blood flow, the bigger the 
tumor) (R2=0.58, p=0.0025). This suggests that some destruction of blood 
microcirculation occurs in C-PDT, and that it stimulates tumor growth (Fig. S5 in the 
Supplementary Materials). 
Interestingly, both V-PDT and C-PDT stimulated superficial tumor blood flow 
when compared with controls (Fig. 5A-D). This may be a consequence of either scab 
healing and/or local inflammation, evidenced by edema and erythema, and it is uncertain 
whether the increased microcirculation has any effect on tumor growth. Edema was much 
more pronounced after V-PDT than after C-PDT. The source of interstitial edema might 
be leakage from vessels or a sign of immune response. Leakage from destroyed 
vasculature should be expected after V-PDT. However, edema correlated with time-to-
tumor volume of 400 mm3 for animals treated with C-PDT (data not shown) but not for 
V-PDT, which suggests that inflammation or low vasculature leakage might have a 
stimulatory effect on tumor growth. Edema of the tumor leg might disturb the blood 
perfusion and pO2 measurements because the larger volume of fluid present in the tissue 
might lead to larger distances to vessels (almost twice, [56]). However, minimal blood 
flow was recorded at 24h after V-PDT while maximal edema was observed at 12h, 
 indicating that edema is not biasing our blood flow measurements. Moreover, blood flow 
measured in the area of vena saphena lateralis was maintained at very low levels for 4 
days, while edema was gradually decreasing. The influence of edema in blood flow 
measurements after C-PDT cannot be excluded. On the other hand, the stronger erythema 
observed after C-PDT did not correlate with microcirculatory perfusion and could be a 
result of inflammation.  
Vascular-targeted PDT led to better the long-term tumor response than cellular-
targeted PDT. Up to 44% animals showed S91 melanoma tumor regression, lasting at 
least one year after therapy. V-PDT led to deep and chronic hypoxia, whereas tumor-
targeted C-PDT caused transient hypoxia, quickly reversed. Figure 10A shows that the 
pO2 decrease due to C-PDT correlates with a pO2 increase in the following 24h. Figure 
10B shows a selection of animals where pO2 level dropped to 0 mmHg at any time after 
illumination. In this sub-set of data, 80% of the animals treated with V-PDT were cured. 
5. Conclusions 
Extremely low pO2 lasting for several days (0-2 mm Hg, i.e. chronic, extreme hypoxia) 
after vascular-targeted PDT favor long-term tumor responses, in contrast to mild and 
transient hypoxia, that in tumor-cell targeted PDT lead to strong pO2 compensatory 
effects (up to 10-12 mm Hg) and frequent tumor re-growths. V-PDT with F2BMet in the 
mouse melanoma model provided significant survival advantage, with a cure rate of 44%. 
This is a remarkable result for one single PDT treatment of malignant melanoma. V-PDT 
with F2BMet is currently in Phase I/II clinical trials. 
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 Figure captions 
Scheme 1. Molecular structure of 5,10,15,20-tetrakis(2,6-difluoro-3-N-
methylsulfamoylphenyl) bacteriochlorin (F2BMet). 
Scheme 2. Experimental setup for Electron Paramagnetic Resonance (left) and Laser 
Doppler Perfusion Imaging (right) measurements. pO2 was determined from the EPR 
spectrum linewidth of the solid state spin probe LiPc. Blood flow LDPI measurements 
were performed at stable ambient temperature of 38 °C. 
Fig. 1. Absorption and fluorescence spectra of F2BMet in PBS:Cremophor EL:ethanol 
vehicle (7.5 µM). The fluorescence was obtained with excitation at 507 nm. 
Fig. 2. Microcirculatory blood perfusion in legs with tumor. (A) Representative black and 
white LDPI image with marked tumor area where the blood perfusion measurement was 
taken. (B-G) Examples of histograms of blood perfusion values in all pixels of the 
measured area, showing the high variety of distributions of blood perfusion values (wide, 
narrow, single- or double peak) in untreated tumors. 
Fig. 3. Representative images showing superficial microcirculatory blood flow in the leg. 
S91 tumor before, 15 min, 3 h and then several time points after V-PDT (A, B) or C-PDT 
(C, D). Blood perfusion in the images was measured in the areas marked (1) vena sapiena 
lateralis, (2) tumor or post-tumor area and (3) skin lesion or scab. (E) Untreated large 
tumor (F) normal untreated leg without tumor. (3.1) Kinetics of blood perfusion after V-
PDT in the same animals as in (A) and (B). (3.2) Kinetics of blood perfusion after C-PDT 
in the same animals as in (C) and (D). Blood perfusion was expressed as the ratio of 
blood perfusion measured in the treated leg to the blood perfusion of the contralateral leg 
in the same animal, with SD indicated.  
Fig. 4. Oxymetric probe localization within the tumor and EPR pO2 measurements (mean 
values with SD) for representative S91 tumors after V- PDT (A, B) and C-PDT (C, D) are 
shown. LiPc crystal position in each tumor was monitored: (A) LiPc was in the upper part 
of the tumor. (B) LiPc was in the upper part of the tumor, slightly smaller than in (A). (C) 
LiPc crystal was in the lower part of the tumor. (D) LiPc was in the middle of the tumor. 
 (4.1) pO2 kinetics of tumors (A) and (B) treated with V-PDT. (4.2) Strongly 
individualized pO2 responses to therapy observed after C-PDT. 
Fig. 5. The kinetics of mean pO2 (squares, left axis) and blood flow (dots, right axis) in 
S91 tumors. Time origin was selected as the moment of irradiation (arrowhead). Tumors 
were treated with: (A) V-PDT, (B) C-PDT, (C) Light only, vehicle injection. (D) PS 
injection, no light. In V-PDT the measurements were discontinued when perfusion 
returned to normal tissue level. N is the initial number of animals in the group. Most 
points were significantly different between C-PDT and V-PDT, whereas controls did not 
differ significantly. Statistical significance was determined using Welch t-test (p<0.05).  
Fig. 6 VEGF level in tumor homogenates collected 24 h after treatment. Number of 
animals in light, untreated and dark controls: N=3; in V-PDT: N=4; in C-PDT: N=5. 
From a single animal two samples were taken. Statistical significance was tested using 
Mann-Whitney U test, * p< 0.05, # p< 0.09. 
Fig. 7. Kaplan Meier plot for animals with S91 tumors treated with V-PDT (N=13), C-
PDT (N=16), and dark (N=7) and light control (N=9). Percentage of animals with tumor 
volume less than 400 mm3 is shown. Animals with tumors > 400 mm3 were sacrificed. 
Differences between all groups were statistically significant as determined by Wilcoxon 
(Gehan) test (p=0.004-0.011), except for light and dark control (p=0.915). Photographs of 
a representative S91 tumor growing in the leg before and after V-PDT (upper) and C-
PDT (lower). Tumor outline is marked in white in the first photograph. Erythema and 
edema are clearly recognized after the treatment.  
Fig. 8. Generation of ROS in PBS assessed by the fluorescence of products generated by 
APF (selective towards hydroxyl radicals) or by SOSG (specific or singlet oxygen). The 
concentrations of the probes were initially 10 µM and F2BMet was 5 µM in each well. 
Fig. 9. (A) Percentage of animals with erythema of the skin of the PDT-treated leg on day 
3 after the therapy. Erythema intensity was scaled from minimal to maximal as 0.5-2, 
with 0 meaning no skin redness. The statistical significance was tested using Fischer 
exact test. (B) Edema of the PDT-treated legs, expressed as % of initial tumor volume 
(mean value with SD). Tumors treated with light and vehicle only increased their volume 
 due to tumor growth (striped), whereas treated tumor volume drastically increased after 
treatment and then decreased in time. Star shows statistical significance (t-test, p<0.05) 
between C-PDT and V-PDT. (C) Relative blood flow in vena sapiena lateralis (leg with 
the tumor/leg without the tumor) showing lack of correlation with edema in (B). * 
p<0.05. 
Fig. 10. (A) ΔpO2 (before – immediately after) vs ΔpO2 (24h – 15 min) for V-PDT (♦) 
and C-PDT (▲), from the data in Fig. 3. (B) Kaplan Meier plot for animals with S91 
tumors treated with V-PDT (Wilcoxon (Gehan) test, p=0.055 , N=2 (>0 mmHg), N=6 (=0 
mm Hg)), showing 80% cure rate of animals in which the pO2 level dropped to 0 mmHg 

































































 Table 1. Concentration of F2BMet in various organs and tissues, in units µg F2BMet / g 
of tissue, 15 min and 72 h after the iv administration of 2 mg/kg in the formulation 
Cremophor:ethanol:NaCl 0.9% (1:1:98) with 5 animals per group. 
 
Organs/Tissues 
15 minutes after injection 72 hours after injection 
F2BMet µg/g tissue SEM F2BMet µg/g tissue SEM 
Blood 11.4 0.723 0.71 0.048 
Tumor 2.55 0.532 5.42 0.903 
Muscle 1.22 0.161 1.27 0.087 
Skin 1.17 0.045 1.44 0.072 
Liver 2.99 0.129 1.71 0.061 
Kidneys 2.52 0.178 1.58 0.055 
Spleen 4.97 0.409 3.11 0.227 
Intestine 1.24 0.176 1.50 0.163 
Lungs 2.86 0.317 1.75 0.219 
Heart 2.25 0.132 1.51 0.076 
 
 
Table 2. Tumor-to-tissue ratios of F2BMet in surrounding tissues such as muscle and skin 




15 minutes after injection 72 hours after injection 
F2BMet µg/g tissue F2BMet µg/g tissue 
Muscle 2.1 4.3 






































































































































































































































F2BMet generates both singlet oxygen and hydroxyl radicals under NIR irradiation 
EPR oximetry informs on hypoxia and Laser Doppler on blood perfusion after PDT 
Persistent local hypoxia after PDT correlates with the cure of S91 melanoma tumors 
Vascular-PDT induces chronic, extreme hypoxia and is more curative than cellular-
PDT

